Ridley David B, Grabowski Henry G, Moe Jeffrey L
Fuqua School of Business, Duke University, Durham, North Carolina, USA.
Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.
Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.
传染病和寄生虫病造成了巨大的健康负担，但由于大多数患有这些疾病的人都很贫困，因此在开发治疗方法方面投入甚少。我们提议，被忽视疾病治疗方法的开发者应获得一张“优先审评券”。这张券平均可节省美国食品药品监督管理局（FDA）一年的审评时间，开发者可将其卖给畅销药制造商。在一个运转良好的市场中，这张券将加快获得高价值治疗方法的速度。因此，这张券能以相对较低的纳税人成本使发展中国家和发达国家的消费者都受益。
